Citations

Clear

3942 citation(s) found for "To, Van".

Vestibular migraine and recurrent vertigo of childhood: Diagnostic criteria consensus document of the Classification Committee of Vestibular Disorders of the Bárány Society and the International Headache Society
Berg, Raymond van de , Widdershoven, Josine , Bisdorff, Alexandre , Evers, Stefan , Wiener‐Vacher, Sylvette , Mack, Kenneth J. , Kim, Ji Soo , Jahn, Klaus , Lempert, Thomas , Kim, Ji‐Soo , Cushing, Sharon Lynn , Strupp, Michael Leo

Mayo Clinic

Journal of Vestibular Research | December 29, 2020 | Volume: 31 | Issue: 1 | Pages: 1-9

10.3233/ves-200003 | PMID 33386837 Get It

This paper describes the diagnostic criteria for “Vestibular Migraine of Childhood”, “probable Vestibular Migraine of Childhood” and “Recurrent Vertigo of Childhood” as put forth by the Committee for the Classification of Vestibular Disorders of the Bárány Society (ICVD) and the Migraine Classification subgroup of the International Headache Society. Migraine plays an important role in some subgroups of children with recurrent vertigo. In this classification paper a spectrum of three disorders is described in which the migraine component varies from definite to possibly absent. These three disorders are: Vestibular Migraine of Childhood, probable Vestibular Migraine of Childhood and Recurrent Vertigo of Childhood. The criteria for Vestibular Migraine of Childhood (VMC) include (A) at least five episodes with vestibular symptoms of moderate or severe intensity, lasting between five minutes and 72 hours, (B) a current or past history of migraine with or without aura, and (C) at least half of episodes are associated with at least one migraine feature. Probable Vestibular Migraine of Childhood (probable VMC) is considered when at least three episodes with vestibular symptoms of moderate or severe intensity, lasting between five minutes and 72 hours, are accompanied by at least criterion B or C from the VMC criteria. Recurrent Vertigo of Childhood (RVC) is diagnosed in case of at least three episodes with vestibular symptoms of moderate or severe intensity, lasting between 1 minute and 72 hours, and none of the criteria B and C for VMC are applicable. For all disorders, the age of the individual needs to be below 18 years old. It is recommended that future research should particularly focus on RVC, in order to investigate and identify possible subtypes and its links or its absence thereof with migraine.
Combined Anterior Transmaxillary (Caldwell-Luc) With an Endoscopic Endonasal Transpterygoid Approach for Resection of a Large Juvenile Nasopharyngeal Angiofibroma: 2-Dimensional Operative Video
Cohen-Cohen, Salomón , Janus, Jeffrey R. , Gompel, Jamie J. Van , Carlstrom, Lucas P. , Van Gompel, Jamie J

Mayo Clinic

Operative Neurosurgery | December 29, 2020 | Volume: 20 | Issue: 3 | Pages: E227-E228

10.1093/ons/opaa375 | PMID 33372963 Get It

Abstract Juvenile nasopharyngeal angiofibroma (JNA) is a highly vascular benign tumor that originates in the sphenopalatine foramen and often spreads to adjacent compartments. 1 Microsurgical resection with preoperative embolization remains the treatment of choice. 2 We present a case of a large JNA involving multiple compartments. The patient is a 20-yr-old male who presented with long-term right nasal congestion. The MRI demonstrated a large enhancing mass that extended from the right nasal cavity and nasopharynx into the right pterygopalatine fossa (PPF), infratemporal fossa (ITF), and parapharyngeal space. Preoperative angiogram for embolization showed a highly vascular tumor with blood supply mainly from the internal maxillary artery and about 10% from a persistent mandibular branch of the internal carotid artery. Based on the UPMC JNA staging system, this tumor was a stage IV. 2 A combined anterior transmaxillary (Caldwell-Luc) with an endoscopic endonasal transpterygoid approach was performed. The addition of the anterior transmaxillary approach increases the surgical freedom for traditional bipolar devices and improves the view and trajectory to more lateral structures like the PPF and ITF. 3 Gross total resection was achieved without complications. The patient was discharged home with a partial V2 numbness (right superior gum) that improved with time. The endoscopic endonasal approach is a safe and effective technique even for large JNA. A multidisciplinary team consisting of an interventional radiologist, a skull base neurosurgeon, and an otorhinolaryngologist with expertise in endoscopic surgery may play a role for optimal surgical results. The patient consented for the procedure and for the video production.
Mesangial matrix expansion in a novel mouse model of diabetic kidney disease associated with the metabolic syndrome
Loon, Elisabet Van , Aboumsallem, Joseph Pierre , Lerut, Evelyne , Bogojevic, Marija , Đenić, Aleksandar , Park, Walter D. , Mishra, Mudit , Naesens, Maarten , Geest, Bart De , Denic, Aleksandar , Park, Walter , Naesens, Maarten , Muthuramu, Ilayaraja , Stegall, Mark D.

Mayo Clinic

Journal of Nephropathology | December 28, 2020 | Volume: 10 | Issue: 2 | Pages: e17-e17

10.34172/jnp.2021.17 Get It

Primary mesenteric sarcomas: Collaborative experience from the Trans‐Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
Tattersall, Hannah L. , Hodson, James , Cardona, Kenneth , Lee, Rachel , Gladdy, Rebecca A. , Hage, Jos A. van der , Schrage, Yvonne , Tseng, William W. , Novak, Marko , Grignani, Giovanni , Tolomeo, Francesco , Ryon, Emily L. , Arnau, Ana Belén Martín , Sayyed, Raza , Tirotta, Fabio , Evenden, Caroline, Glasbey, James , Ford, Samuel , Lee, Rachel M , Tseng, William W , Bagaria, Sanjay P , Tirotta, Fabio , Fiore, Marco , Grignani, Giovanni , Nessim, Carolyn , Houdt, Winan J. van , Goel, Neha , Gyorki, David E. , Bagaria, Sanjay P. , Gonzalez, Jose A., Desai, Anant , Almond, Max , Fiore, Marco , Gronchi, Alessandro

Mayo Clinic

Journal of Surgical Oncology | December 24, 2020 | Volume: 123 | Issue: 4 | Pages: 1057-1066

10.1002/jso.26353 | PMID 33368277 Get It

AbstractBackgroundPrimary mesenteric soft tissue sarcomas (STS) are rare and limited evidence is available to inform management. Surgical resection is challenging due to the proximity of vital structures and a need to preserve enteric function.ObjectivesTo determine the overall survival (OS) and recurrence‐free survival (RFS) for patients undergoing primary resection for mesenteric STS.MethodsThe Trans‐Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) is an intercontinental collaborative comprising specialist sarcoma centers. Data were collected retrospectively for all patients with mesenteric STS undergoing primary resection between 2000 and 2019.ResultsFifty‐six cases from 15 institutions were included. The spectrum of pathology was similar to the retroperitoneum, although of a higher grade. R0/R1 resection was achieved in 87%. Median OS was 56 months. OS was significantly shorter in higher‐grade tumors (p = .018) and extensive resection (p < .001). No significant association between OS and resection margin or tumor size was detected. Rates of local recurrence (LR) and distant metastases (DM) at 5 years were 60% and 41%, respectively. Liver metastases were common (60%), reflecting portal drainage of the mesentery.ConclusionPrimary mesenteric sarcoma is rare, with a modest survival rate. LR and DM are frequent events. Liver metastases are common, highlighting the need for surveillance imaging.
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Ng, Casey K. , Loo, Ronald K., Jacobsen, Steven J. , Tan, Wei Shen , Kelly, John D. , Lough, Tony, Darling, David, Kessel, Kim E.M. van, Jong, Joep J. de , Criekinge, Wim Van , Hiar, Andrew M., Boorjian, Stephen A. , Barocas, Daniel A. , Svatek, Robert S. , Woldu, Solomon L , Slezak, Jeff M. , Shariat, Shahrokh F. , Brown, Sarah, Lotan, Yair

Mayo Clinic

Journal of Urology | December 24, 2020 | Volume: 205 | Issue: 5 | Pages: 1387-1393

10.1097/ju.0000000000001550 | PMID 33356483 Get It

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Neelapu, Sattva S. , Adkins, Sherry , Ansell, Stephen M. , Cairo, Mitchell S. , Friedberg, Jonathan W. , Levy, Ronald , Porter, David L. , Bishop, Michael R. , Cairo, Mitchell , Brody, Joshua , Kline, Justin Paul , Besien, Koen van , Werner, Michael, Bishop, Michael Russell

Mayo Clinic

Journal for ImmunoTherapy of Cancer | December 24, 2020 | Volume: 8 | Issue: 2 | Pages: e001235

10.1136/jitc-2020-001235 | PMID 33361336 Get It

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.
A sound method for axillary vein access
Zyl, Martin van , Deshmukh, Abhishek , van Zyl, Martin , Deshmukh, Abhishek J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 18, 2020 | Volume: 32 | Issue: 2 | Pages: 466-467

10.1111/jce.14839 | PMID 33337565 Get It

Outcomes following surgical management of vagus nerve stimulator–related infection: a retrospective multi-institutional study
Marsh, W. Richard , Wharen, Robert E. , Zimmerman, Richard S. , Burkholder, David B. , Meyer, Fredric B. , Burkholder, David B , Hasegawa, Hirotaka , Gompel, Jamie J. Van , Lundstrom, Brian N. , Britton, Jeffrey W.

Mayo Clinic

Journal of Neurosurgery | December 18, 2020 | Volume: 135 | Issue: 3 | Pages: 783-791

10.3171/2020.7.jns201385 | PMID 33339002 Get It

OBJECTIVE Surgical site infection (SSI) is a rare but significant complication after vagus nerve stimulator (VNS) placement. Treatment options range from antibiotic therapy alone to hardware removal. The optimal therapeutic strategy remains open to debate. Therefore, the authors conducted this retrospective multicenter analysis to provide insight into the optimal management of VNS-related SSI (VNS-SSI). METHODS Under institutional review board approval and utilizing an institutional database with 641 patients who had undergone 808 VNS-related placement surgeries and 31 patients who had undergone VNS-related hardware removal surgeries, the authors retrospectively analyzed VNS-SSI. RESULTS Sixteen cases of VNS-SSI were identified; 12 of them had undergone the original VNS placement procedure at the authors’ institutions. Thus, the incidence of VNS-SSI was calculated as 1.5%. The mean (± standard deviation) time from the most recent VNS-related surgeries to infection was 42 (± 27) days. Methicillin-sensitive staphylococcus was the usual causative bacteria (58%). Initial treatments included antibiotics with or without nonsurgical procedures (n = 6), nonremoval open surgeries for irrigation (n = 3), generator removal (n = 3), and total or near-total removal of hardware (n = 4). Although 2 patients were successfully treated with antibiotics alone or combined with generator removal, removal of both the generator and leads was eventually required in 14 patients. Mild swallowing difficulties and hoarseness occurred in 2 patients with eventual resolution. CONCLUSIONS Removal of the VNS including electrode leads combined with antibiotic administration is the definitive treatment but has a risk of causing dysphagia. If the surgeon finds dense scarring around the vagus nerve, the prudent approach is to snip the electrode close to the nerve as opposed to attempting to unwind the lead completely.
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Perrot, Aurore , Plesner, Torben , Usmani, Saad Z. , Kumar, Shaji , Hulin, Cyrille , Orlowski, Robert Z. , Nahi, Hareth , Mollee, Peter , Ramasamy, Karthik , Roussel, Murielle , Jaccard, Arnaud , Delforge, Michel , Karlin, Lionel, Arnulf, Bertrand , Chari, Ajai , He, Jianming , Ho, Kai Fai, Rampelbergh, Rian Van , Uhlar, Clarissa, Wang, Jianping , Kobos, Rachel, Gries, Katharine S. , Fastenau, John , Orlowski, Robert Z. , Jaccard, Arnaud , Chari, Ajai , Perrot, Aurore , Ramasamy, Karthik , Usmani, Saad , Nahi, Hareth , Roussel, Murielle , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Karlin, Lionel , Weisel, Katja C

Mayo Clinic

Journal of Clinical Oncology | December 16, 2020 | Volume: 39 | Issue: 3 | Pages: 227-237

10.1200/jco.20.01370 | PMID 33326255 Get It

PURPOSE To evaluate the effects of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) on patient-reported outcomes (PROs) in the phase III MAIA study. PATIENTS AND METHODS PROs were assessed on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item and the EuroQol 5-dimensional descriptive system at baseline and every 3 months during treatment. By mixed-effects model, changes from baseline are presented as least squares means with 95% CIs. RESULTS A total of 737 transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma were randomly assigned to D-Rd (n = 368) or Rd (n = 369). Compliance with PRO assessments was high at baseline (> 90%) through month 12 (> 78%) for both groups. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item global health status scores improved from baseline in both groups and were consistently greater with D-Rd at all time points. A global health status benefit was achieved with D-Rd, regardless of age (< 75 and ≥ 75 years), baseline Eastern Cooperative Oncology Group (ECOG) performance status score, or depth of response. D-Rd treatment resulted in significantly greater reduction in pain scores as early as cycle 3 ( P = .0007 v Rd); the magnitude of change was sustained through cycle 12. Reductions in pain with D-Rd were clinically meaningful in patients regardless of age, ECOG status, or depth of response. Similarly, PRO improvements were observed with D-Rd and Rd on the EuroQol 5-dimensional descriptive system visual analog scale score. CONCLUSION D-Rd compared with Rd was associated with faster and sustained clinically meaningful improvements in PROs, including pain, in transplant-ineligible patients with newly diagnosed multiple myeloma regardless of age, baseline ECOG status, or depth of treatment response.
Low‐Dose Tamoxifen Induces Significant Bone Formation in Mice
McGrath, Cody , Sankaran, Jeyantt Srinivas , Styner, Maya , Little, Sarah E , Dudakovic, Amel , Wijnen, André J. van , Rubin, Janet , Sen, Buer , Styner, Maya , Dudakovic, Amel , Rubin, Janet , Sen, Buer , van Wijnen, Andre J , Xie, Zhihui

Mayo Clinic

JBMR Plus | December 10, 2020 | Volume: 5 | Issue: 3 | Pages: No page available

10.1002/jbm4.10450 | PMID 33778320 Get It

ABSTRACT Use of the selective estrogen receptor modulator Tamoxifen (TAM) is a mainstay to induce conditional expression of Cre recombinase in transgenic laboratory mice. To excise β‐catenin fl/fl in 28‐day‐old male and female Prrx1‐CreER/β‐catenin fl/fl mice (C57BL/6), we utilized TAM at 150 mg/kg; despite β‐catenin knockout in MSC, we found a significant increase in trabecular and cortical bone volume in all genders. Because TAM was similarly anabolic in KO and control mice, we investigated a dose effect on bone formation by treating wild‐type mice (WT C57BL/6, 4 weeks) with TAM (total dose 0, 20, 40, 200 mg/kg via four injections). TAM increased bone in a dose‐dependent manner analyzed by micro–computed tomography (μCT), which showed that, compared to control, 20 mg/kg TAM increased femoral bone volume fraction (bone volume/total volume [BV/TV]) (21.6% ± 1.5% to 33% ± 2.5%; 153%, p < 0.005). With TAM 40 mg/kg and 200 mg/kg, BV/TV increased to 48.1% ± 4.4% (223%, p < 0.0005) and 58% ± 3.8% (269%, p < 0.0001) respectively, compared to control. Osteoblast markers increased with 200 mg/kg TAM: Dlx5 (224%, p < 0.0001), Alp (166%, p < 0.0001), Bglap (223%, p < 0.0001), and Sp7 (228%, p < 0.0001). Osteoclasts per bone surface (Oc#/BS) nearly doubled at the lowest TAM dose (20 mg/kg), but decreased to <20% control with 200 mg/kg TAM. Our data establish that use of TAM at even very low doses to excise a floxed target in postnatal mice has profound effects on trabecular and cortical bone formation. As such, TAM treatment is a major confounder in the interpretation of bone phenotypes in conditional gene knockout mouse models. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.